Conditions: Immune Thrombocytopenia (ITP)
Keywords: Blood Platelet Disorders Immune Thrombocytopenia (ITP) Low Platelet Count Thrombocytopaenia S-888711 Splenectomy Thrombopoiesis Hematologic Disease Auto-immune thrombocytopenic Purpura Relapsed Persistent or Chronic ITP Idiopathic Thrombocytopenic Purpura Thrombotic Thrombocytopenic Purpura (TTP)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 20
Healthy volunteers: no

Brief summary:
The primary objective of this study was to assess the efficacy of 3 dose levels of lusutrombopag (0.5 mg, 0.75 mg, and 1.0 mg) and placebo on platelet count.

Detailed description:

Arms:
arm 1: Participants received placebo tablets orally once a day for 42 days. arm 2: Participants received 0.5 mg lusutrombopag orally once a day for 42 days. arm 3: Participants received 0.75 mg lusutrombopag orally once a day for 42 days. arm 4: Participants received 1.0 mg lusutrombopag orally once a day for 42 days.

Interventions: intervention 1: Placebo intervention 2: Lusutrombopag
Intervention descriptions: intervention 1: Tablet intervention 2: Tablet

Protocol document: